• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Research and development > Portfolio

Pandemic Preparedness 

TMEM16 series

objective

Develop optimized salicylamide derivatives with an improved drug property profile as broad-spectrum antivirals

project start
2022

current phase of drug development

Discovery project phase
Drug Discovery
Translation project phase
Translational research
clinical trials icon
Clinical trials
Treatment Access
Registration & access

updated 11 Mar 2025

DNDi is collaborating with the Translational Health Science and Technology Institute (THSTI) Faridabad, India, to identify affordable antiviral drugs effective against Influenza and other viruses of pandemic potential. The project focuses on the synthesis and optimization of novel salicylamide derivatives, which show potent antiviral activity against a range of different virus families, including orthomyxo, corona, and flaviviruses, with a low potential for the development of drug-induced resistance.

The current aim is to identify compound candidates with improved human plasma exposure compared to existing drugs – such as niclosamide and nitazoxanide – and to select a lead candidate compound suitable for pre-clinical studies. The project includes medicinal chemistry and pharmacokinetic studies, antiviral testing, and pharmacological evaluation.

Compounds included in the study will be analysed and assessed in two steps:

  1. Medicinal chemistry and pharmacokinetic studies of novel salicylamide derivatives
  2. Antiviral test cascade and pharmacological evaluation in vitro and in vivo of suitable lead compounds

All medicinal chemistry work is being performed in India with the goal of further strengthening academic drug discovery research in the country. The results of the project will be shared widely through open access publications.

Project updates

2024

New salicylamide derivatives with improved physiochemical profiles have been designed and synthesized, confirming that it is feasible to significantly improve the drug property profiles of compounds in the series. Work is now focused on improving the antiviral potency of the compounds in the sub-series and confirming a favourable plasma exposure profile before assessing in vivo antiviral efficacy.

2023

Salicylamides such as niclosamide and nitazoxanide exhibit potent antiviral activity for a broad range of different viruses, including SARS-CoV-2, dengue, and influenza viruses. The antiviral mechanism of action is not yet fully understood, although it is suggested that they act through host mechanisms by blocking key steps in viral uptake and excretion. Furthermore, it is reported that the antiviral activity is dependent on the interaction with the TMEM16F Ca2+ ion-channel/scramblase. Significant progress in 2023 included the identification of novel analogues showing improved microsomal clearance and the development of an improved understanding of antiviral structure relationships.

News & resources

  • 1 April 2024 – Pandemic preparedness: DNDi and THSTI receive financial support from Novo Nordisk Foundation to develop broad-spectrum, host-directed antivirals

Partners

  • Indian Institute of Technology-Gandhinagar (IIT-G), India
  • Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management (SVKM’s NMIMS), India
  • Translational Health Science and Technology Institute (THSTI), India
Loading…
  • Indian Institute of Technology-Gandhinagar (IIT-G)
  • ,India
  • Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management (SVKM’s NMIMS)
  • ,India
  • Translational Health Science and Technology Institute (THSTI)
  • ,India
  • Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management (SVKM’s NMIMS), India
  • Indian Institute of Technology-Gandhinagar (IIT-G), India
  • Translational Health Science and Technology Institute (THSTI), India

Funding

  • Germany - Federal Ministry of Education and Research (BMBF) through KfW
​
​

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License